Highbridge Capital Management’s Krystal Biotech KRYS Stock Holding History

Highbridge Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-68,959	Closed	-$1.02M	–	697
2018 Q2	$1.02M	Sell	68,959 -231,041	-77%	-$2.6M	0.02%	470
2018 Q1	$3.03M	Hold	300,000	–	–	0.05%	379
2017 Q4	$3.16M	Hold	300,000	–	–	0.06%	322
2017 Q3	$2.99M	Buy	+300,000	New	+$3.02M	0.04%	370

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

TCP

Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SST

S Squared Technology New York $264M AUM 73.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Highbridge Capital Management's KRYS Position: Q3 2018 in Review

Highbridge Capital Management sold out of Krystal Biotech (KRYS) in Q3 2018, closing a stake of 68,959 shares — an estimated $1.02M sold.

Highbridge Capital Management first reported a position in KRYS in Q3 2017 and held it in 4 quarters. The position peaked at $3.16M in Q4 2017. 23 funds tracked by Wall St. Rank hold KRYS as of Q3 2018.

Highbridge Capital Management reported no remaining Krystal Biotech position as of Q3 2018 after selling out during the quarter.
Highbridge Capital Management sold 68,959 Krystal Biotech shares in Q3 2018, an estimated $1.02M.
Highbridge Capital Management first reported a position in Krystal Biotech in Q3 2017 and held it in 4 quarters.
Highbridge Capital Management's Krystal Biotech position peaked at $3.16M in Q4 2017.
23 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2018.

Based on Highbridge Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.